Skip to main content
Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc. — Investor Relations & Filings

Ticker · JSPR ISIN · US4718712023 US Professional, scientific and technical activities
Filings indexed 421 across all filing types
Latest filing 2025-05-19 Annual Report
Country US United States of America
Listing US JSPR

About Jasper Therapeutics, Inc.

https://jaspertx.com/

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company that develops therapies targeting mast and hematopoietic stem cells. The company's lead product candidate is briquilimab, a monoclonal antibody that targets c-Kit (CD117). This therapeutic is designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. Jasper Therapeutics is conducting clinical studies to evaluate briquilimab in patients with chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to provide safer and more effective therapies for patients with chronic mast cell-driven diseases.

Recent filings

Filing Released Lang Actions
FORM ARS
Annual Report
2025-05-19 English
DEFINITIVE ADDITIONAL MATERIALS
Regulatory Filings
2025-05-19 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2025-05-19 English
CURRENT REPORT
Regulatory Filings
2025-05-12 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2025
2025-05-12 English
Regulatory Filings 2025
Regulatory Filings
2025-03-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.